Sangamo Therapeutics announces $24M registered direct offering of common stock and warrants

SANGAMO THERAPEUTICS, INC

Offering includes 24.8M shares, 3.8M pre-funded warrants, and 28.6M purchase warrants at $0.84/unit.
Gross proceeds expected ~$24.0M; closing on or about March 26, 2024.
Placement agents: Barclays Capital Inc. and Cantor Fitzgerald & Co.; 6% cash fee.
Pre-funded warrant exercise price $0.01; purchase warrant exercise price $1.00 with 5.5-year term.
Lock-Up Agreements from directors and officers restrict share sales for a period.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.